Knopp Biosciences
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2100 Wharton St Ste 615, Pittsburgh, Pen...Phone Number
(412) 488-1776Website
www.knoppbio.comRevenue
$5.2 MillionIndustry
About Knopp Biosciences
Knopp Biosciences LLC is a privately held company focused on drug discovery for immunological and neurological diseases. The company is developing dexpramipexole for eosinophilic asthma and has a Kv7 platform for epilepsy treatments, which is being advanced by Biohaven Pharmaceuticals. Founded in 2004, Knopp manages a portfolio of equity securities and product royalties. Their investor portal will provide updates and proprietary information to members starting Spring 2023.Explore more
Knopp Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Knopp Biosciences
Compare insights from companies similar to Knopp Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Knopp Biosciences Tech Stack
A closer look at the technologies used by Knopp Biosciences
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Knopp Biosciences
Sign Up For FreeTo access detailed company insights
Knopp Biosciences LLC is a privately held company focused on drug discovery for immunological and neurological diseases. The company is developing dexpramipexole for eosinophilic asthma and has a Kv7 platform for epilepsy treatments, which is being advanced by Biohaven Pharmaceuticals. Founded in 2004, Knopp manages a portfolio of equity securities... Read More
